<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="causing mild to severe diseases. The ongoing pandemic of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) represents a global threat,"/>
 <result pre="mild to severe diseases. The ongoing pandemic of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) represents a global threat, urging"/>
 <result pre="to severe diseases. The ongoing pandemic of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) represents a global threat, urging the"/>
 <result pre="genome varying from 25 to 32 kb (Payne, 2017). The" exact="viral" post="structure is primarily formed by the structural spike (S),"/>
 <result pre="The S, M, and E proteins are embedded in the" exact="viral" post="envelope, which is a lipid bilayer derived from the"/>
 <result pre="The N protein, on the other hand, interacts with the" exact="viral" post="RNA into the core of the virion (Figure 1;"/>
 <result pre="and Perlman, 2015). FIGURE 1 Schematic structure of SARS-CoV-2. The" exact="viral" post="structure is primarily formed by the structural proteins such"/>
 <result pre="S, M, and E proteins are all embedded in the" exact="viral" post="envelope, a lipid bilayer derived from the host cell"/>
 <result pre="the host cell membrane. The N protein interacts with the" exact="viral" post="RNA in to the core of the virion. These"/>
 <result pre="of the virion. These viruses can infect vertebrate animals, causing" exact="acute" post="to chronic diseases in the respiratory, cardiac, enteric, and"/>
 <result pre="virion. These viruses can infect vertebrate animals, causing acute to" exact="chronic" post="diseases in the respiratory, cardiac, enteric, and central nervous"/>
 <result pre="and Navas-Martin, 2005). In animals, the most common CoVs are" exact="infectious" post="bronchitis virus (IBV), feline CoV (FeCoV), and mouse hepatitis"/>
 <result pre="Navas-Martin, 2005). In animals, the most common CoVs are infectious" exact="bronchitis" post="virus (IBV), feline CoV (FeCoV), and mouse hepatitis virus"/>
 <result pre="are infectious bronchitis virus (IBV), feline CoV (FeCoV), and mouse" exact="hepatitis" post="virus (MHV), which infect chickens, felines, and rodents, respectively"/>
 <result pre="that cause diseases in humans: HCoV-229E, HCoV-NL63, HCoV-OC43, HCoV-HKU1, severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus"/>
 <result pre="cause diseases in humans: HCoV-229E, HCoV-NL63, HCoV-OC43, HCoV-HKU1, severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV)"/>
 <result pre="diseases in humans: HCoV-229E, HCoV-NL63, HCoV-OC43, HCoV-HKU1, severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV) and,"/>
 <result pre="HCoV-OC43, HCoV-HKU1, severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) and, most recently, SARS-CoV-2 (Graham et"/>
 <result pre="HCoV-HKU1, severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) and, most recently, SARS-CoV-2 (Graham et al.,"/>
 <result pre="and SARS-CoV-2 can cause mild to severe symptoms related to" exact="upper respiratory infection" post="such as fever, cough, dyspnea, pneumonia, and acute respiratory"/>
 <result pre="SARS-CoV-2 can cause mild to severe symptoms related to upper" exact="respiratory" post="infection such as fever, cough, dyspnea, pneumonia, and acute"/>
 <result pre="can cause mild to severe symptoms related to upper respiratory" exact="infection" post="such as fever, cough, dyspnea, pneumonia, and acute respiratory"/>
 <result pre="upper respiratory infection such as fever, cough, dyspnea, pneumonia, and" exact="acute" post="respiratory distress syndrome (ARDS), ultimately leading to death (Lai"/>
 <result pre="respiratory infection such as fever, cough, dyspnea, pneumonia, and acute" exact="respiratory" post="distress syndrome (ARDS), ultimately leading to death (Lai et"/>
 <result pre="such as fever, cough, dyspnea, pneumonia, and acute respiratory distress" exact="syndrome" post="(ARDS), ultimately leading to death (Lai et al., 2020)."/>
 <result pre="recipient individuals are in close contact (about one meter). These" exact="infectious" post="oral and respiratory droplets produced by talking, coughing, sneezing"/>
 <result pre="in close contact (about one meter). These infectious oral and" exact="respiratory" post="droplets produced by talking, coughing, sneezing need to contact"/>
 <result pre="with mouth, nose, or eyes (van Doremalen et al., 2020)." exact="Viral" post="particles may remain viable on surfaces for several days,"/>
 <result pre="viable on surfaces for several days, increasing the probability of" exact="infection" post="by third parties (van Doremalen et al., 2020). Recently,"/>
 <result pre="virus across the world so that it became a pandemic" exact="disease" post="in just a few months (CDC, 2020a; Wu et"/>
 <result pre="subunit, a fusion peptide that allows the fusion of the" exact="viral" post="envelope with the endosome membrane, and consequently, releases the"/>
 <result pre="2009; Matsuyama et al., 2020). In the cytoplasm, the CoV" exact="viral" post="genome is uncoated, and the viral RNA is released."/>
 <result pre="the cytoplasm, the CoV viral genome is uncoated, and the" exact="viral" post="RNA is released. The positive-sense RNA viral genome is"/>
 <result pre="uncoated, and the viral RNA is released. The positive-sense RNA" exact="viral" post="genome is translated to produce nonstructural proteins (nsps) from"/>
 <result pre="cleaved into 15 nsps. The proteolytic cleavage is performed by" exact="viral" post="proteases nsp3 and nsp5 (Yogo et al., 1977; Lai"/>
 <result pre="The sgRNAs act as mRNAs for structural and accessory genes" exact="localized" post="downstream of the replicase polyproteins. SARS-CoV-2 has six accessory"/>
 <result pre="the endoplasmic reticulum (ER) and are subsequently inserted into an" exact="intermediate" post="compartment of ER with Golgi (ERGIC). There, viral genomes"/>
 <result pre="into an intermediate compartment of ER with Golgi (ERGIC). There," exact="viral" post="genomes are encapsulated by N proteins and assembled with"/>
 <result pre="nucleocapsid, and then, the S protein is incorporated, forming a" exact="complete" post="virion. Finally, the virions are transported to the cell"/>
 <result pre="interaction between the ACE2 receptors and spike proteins. After entry," exact="viral" post="uncoating process results in the release of viral genome"/>
 <result pre="After entry, viral uncoating process results in the release of" exact="viral" post="genome and replication stage occurs (translation and transcription). Structural"/>
 <result pre="of viral genome and replication stage occurs (translation and transcription)." exact="Structural" post="proteins are produced in intermediate compartment of endoplasmic reticulum"/>
 <result pre="stage occurs (translation and transcription). Structural proteins are produced in" exact="intermediate" post="compartment of endoplasmic reticulum with Golgi complex and forwarded"/>
 <result pre="and investigation of potential ligands toward target molecules in the" exact="viral" post="structure and/or replication (Ahmed et al., 2020, 2; Jeon"/>
 <result pre="cellular response or the effects of the compounds on the" exact="viral" post="replicative cycle (Roberts et al., 2006; Hoffmann et al.,"/>
 <result pre="efforts are concentrated on using approaches such as mRNA, DNA," exact="viral" post="vectors, or virus-like particles vaccines with a full-length S"/>
 <result pre="(Mullard, 2020; Tu et al., 2020). The high transmissibility and" exact="viral" post="variability of the novel SARS-CoV-2, along with the lack"/>
 <result pre="able to reduce the severity of clinical outcomes of coronavirus" exact="disease" post="2019 (COVID-19) and to reduce the spread of SARS-CoV-2."/>
 <result pre="with a broad-spectrum effect (human and animal CoVs); protected against" exact="infection" post="and improved survival in animal assay (Balb/c) Oâ€™Keefe et"/>
 <result pre="Î¼M FIPV The precursor molecule (Eremomycin) is used to treat" exact="bacterial infections;" post="may facilitate clinical assays, but knowledge of the mechanism"/>
 <result pre="Î¼M SARS-CoV Synthetic molecule, highly tolerated, easily produced, and improved" exact="pulmonary" post="function and decreased viral load in lung of infected"/>
 <result pre="highly tolerated, easily produced, and improved pulmonary function and decreased" exact="viral" post="load in lung of infected mice Barnard et al.,"/>
 <result pre="tolerated, easily produced, good results in MERS-CoV. However, meta-analyses indicate" exact="limited" post="efficacy. Saijo et al., 2005; Barnard et al., 2006"/>
 <result pre="0.92 Î¼g mLâ€&quot;1 MERS-CoV Drug already in use to treat" exact="viral" post="infections; good inhibition in vitro Rossignol, 2016 Tizoxanide Host"/>
 <result pre="Î¼M MERS-CoV Synthetic molecule, highly tolerated, used to treat Alzheimerâ€™s" exact="disease" post="and easily produced but there are no in vivo"/>
 <result pre="SARS-CoV, MERS-CoV and MHV Drug already used to treat several" exact="chronic" post="and infectious diseases with broad-spectrum activity among CoVs de"/>
 <result pre="and MHV Drug already used to treat several chronic and" exact="infectious diseases" post="with broad-spectrum activity among CoVs de Wilde et al.,"/>
 <result pre="other CoVs de Wilde et al., 2017 Interference RNA (iRNAs)" exact="Viral" post="Proteins Translation 70% SARS-CoV Different approach, specific targeting of"/>
 <result pre="Viral Proteins Translation 70% SARS-CoV Different approach, specific targeting of" exact="viral" post="proteins; can block replication steps and has no cytotoxicity"/>
 <result pre="replication steps and has no cytotoxicity Ã…kerstrÃ¶m et al., 2007" exact="Viral" post="Proteins Translation 99% SECoV Different approach, specific targeting of"/>
 <result pre="Viral Proteins Translation 99% SECoV Different approach, specific targeting of" exact="viral" post="proteins; can block replication steps and has no cytotoxicity"/>
 <result pre="(controlling immune response) NE Clinical trial with 454 treated patients" exact="Reduced" post="death by one-third in invasive mechanical ventilation patients and"/>
 <result pre="ventilation patients; however, did not impair mortality in patients without" exact="respiratory" post="support This is a multicentre, double-blind, placebo-controlled clinical trial."/>
 <result pre="ventilatory support in patients Tocilizumab is already used to treat" exact="viral" post="infections, controlling immune response, impairing cytokine storms, improving antiviral"/>
 <result pre="patients since it is related to donor-dependent variability and compatibility." exact="Antibody" post="titers may interfere with its activity. In addition, it"/>
 <result pre="addition, it might cause side effects in lung and the" exact="cardiovascular" post="system. EC50: effective concentration of 50%; NE: not evaluated."/>
 <result pre="the host cells is mainly related to the binding of" exact="viral" post="S protein to the ACE2 receptor (Prabakaran et al.,"/>
 <result pre="suggesting that NAAE might be a candidate for treating SARS" exact="infection" post="by impairing viral attachment via interference with ACE2 (Huentelman"/>
 <result pre="might be a candidate for treating SARS infection by impairing" exact="viral" post="attachment via interference with ACE2 (Huentelman et al., 2004b)."/>
 <result pre="GL was less effective when the administration occurred during the" exact="viral" post="adsorption period than when it was administered after entry"/>
 <result pre="the case of 2-acetamido-Î±- D-glucopyranosylamine derivative, it was speculated that" exact="viral" post="entry was inhibited through N-acetylglycosamine binding onto S-protein carbohydrates."/>
 <result pre="higher cytotoxicity profile. The endossomal cathepsins are essential enzymes in" exact="viral" post="entry into host cells (Huang et al., 2006), and"/>
 <result pre="a luciferase reporter to infect 293T cells, the compound inhibited" exact="viral" post="entry with an EC50 of 273 Î·M and CC50"/>
 <result pre="that the compound CID 23631927 seems to bind with a" exact="lower" post="inhibition constant (Ki) to cathepsin L, improving the compound/cathepsin"/>
 <result pre="100 Î¼M). Conversely, [(Z)-1-thiophen-2-ylethylideneamino]thiourea (SSAA09E3) prevented the fusion of the" exact="viral" post="envelope with host membrane cells by direct interaction with"/>
 <result pre="with antiviral activities and presented good oral bioavailability and rapid" exact="systemic" post="distribution in animal models, they might exhibit interesting pharmacokinetics"/>
 <result pre="that emodin might be impairing virus release by affecting 3a" exact="viral" post="protein, which is related to ion channels in infected"/>
 <result pre="from the red alga Griffithsia sp. that has shown powerful" exact="viral" post="entry inhibition against several enveloped viruses, such as the"/>
 <result pre="entry inhibition against several enveloped viruses, such as the human" exact="immunodeficiency" post="virus (HIV). GRFT is capable of binding to terminal"/>
 <result pre="binding to terminal mannoses of oligosaccharides and also to glycans" exact="localized" post="on the viral envelope glycoproteins (Lusvarghi and Bewley, 2016)."/>
 <result pre="mannoses of oligosaccharides and also to glycans localized on the" exact="viral" post="envelope glycoproteins (Lusvarghi and Bewley, 2016). GFRT did not"/>
 <result pre="GFRT did not present cytotoxicity in Vero cells, human ileocecal" exact="colorectal adenocarcinoma" post="cells, human diploid fibroblast cells, and rhesus monkey kidney"/>
 <result pre="did not present cytotoxicity in Vero cells, human ileocecal colorectal" exact="adenocarcinoma" post="cells, human diploid fibroblast cells, and rhesus monkey kidney"/>
 <result pre="In another study, GRFT inhibited the early stages of MERS-CoV" exact="infection" post="in HEK-293T cells (Millet et al., 2016). Furthermore, GRFT"/>
 <result pre="GRFT improved survival in SARS-CoV-infected mice and protected the Balb/c" exact="female" post="mice against infection by binding with S protein (Oâ€™Keefe"/>
 <result pre="in SARS-CoV-infected mice and protected the Balb/c female mice against" exact="infection" post="by binding with S protein (Oâ€™Keefe et al., 2010)."/>
 <result pre="chemotherapeutics. Vancomycin, eremomycin, and teicoplanin glycopeptide compounds used to treat" exact="infections" post="caused by Gram-positive bacteria (Preobrazhenskaya and Olsufyeva, 2004), as"/>
 <result pre="then optimized synthetically, generating mucroporin-M1, which was able to inhibit" exact="measles" post="virus (MeV), SARS-CoV, and influenza H5N1. Specifically, mucroporin M-1"/>
 <result pre="the hydrophilic site, which can enhance the interaction with the" exact="viral" post="surface, inactivating the viral particle. Other potential antiviral peptides"/>
 <result pre="can enhance the interaction with the viral surface, inactivating the" exact="viral" post="particle. Other potential antiviral peptides were selected by Struck"/>
 <result pre="the hexapeptide Tyr-Lys-Tyr-Arg-Tyr-Leu at 14 mM inhibited SARS-CoV and HCoV-NL63" exact="infection" post="in Vero cells without triggering cytotoxicity (Struck et al.,"/>
 <result pre="metabolism. Taking into consideration that cellular factors such as the" exact="Tumor" post="Necrosis Factor-alpha (TNF-Î±) converting enzyme (TACE) facilitate SARS-CoV entry"/>
 <result pre="and L-SIGN (Jeffers et al., 2004; Han et al., 2007)," exact="viral" post="entry might be not be impaired by this molecule."/>
 <result pre="antibodies (mAbs) have attracted attention due to their use in" exact="infectious" post="and chronic disease treatments (Green et al., 2000; Haynes"/>
 <result pre="have attracted attention due to their use in infectious and" exact="chronic" post="disease treatments (Green et al., 2000; Haynes et al.,"/>
 <result pre="attracted attention due to their use in infectious and chronic" exact="disease" post="treatments (Green et al., 2000; Haynes et al., 2009;"/>
 <result pre="human CoVs have been generated, targeting S glycoproteins to impair" exact="viral" post="entry (Belouzard et al., 2012; Reguera et al., 2012)."/>
 <result pre="several mAbs were identified as inhibitors of MERS-CoV and SARS-CoV" exact="infections" post="both in vitro and in vivo, protecting cells and"/>
 <result pre="2020). The mAbs are developed by merging B lymphocytes and" exact="myeloma" post="cells, producing hybridomas capable of recognizing antigens and producing"/>
 <result pre="Replicative Cycle Among the proteins that are pivotal for CoV" exact="viral" post="replication are the main proteases (Mpro) such as the"/>
 <result pre="protease (3CLpro) and the papain-like proteases (PPL). These enzymes process" exact="viral" post="polyproteins and control replicase complex activity (Anand et al.,"/>
 <result pre="the compound was not efficient in reducing the effects of" exact="viral" post="replication in BALB/c mice (Day et al., 2009). The"/>
 <result pre="showed that GC373 inhibited HCoV-229E (EC50 of 0.2 Î¼M), feline" exact="infectious" post="peritonitis virus (FIPV, EC50 of 0.3 Î¼M), MHV (EC50"/>
 <result pre="that GC373 inhibited HCoV-229E (EC50 of 0.2 Î¼M), feline infectious" exact="peritonitis" post="virus (FIPV, EC50 of 0.3 Î¼M), MHV (EC50 of"/>
 <result pre="EC50 of 0.3 Î¼M), MHV (EC50 of 2 Î¼M), transmissible" exact="gastroenteritis" post="virus (TGEV, EC50 of 0.3 Î¼M), and bovine coronavirus"/>
 <result pre="(RdRp) also figures as a promising target for antivirals. In" exact="viral" post="replication, RdRp is responsible for catalyzing the replication of"/>
 <result pre="replication, RdRp is responsible for catalyzing the replication of the" exact="viral" post="RNA using a complementary RNA as a template. Therefore,"/>
 <result pre="interfere in this process are excellent drug candidates for treating" exact="viral" post="infections (Ganeshpurkar et al., 2019). Nucleoside analogs of pyrimidine"/>
 <result pre="in this process are excellent drug candidates for treating viral" exact="infections" post="(Ganeshpurkar et al., 2019). Nucleoside analogs of pyrimidine interfere"/>
 <result pre="of pyrimidine interfere in uridine triphosphate (UTP) metabolism, directly affecting" exact="viral" post="replication (Murphy and Middleton, 2012), as demonstrated by Î²-"/>
 <result pre="the NHC effect in SARS-CoV- and MERS-CoV-infected mice. NHC improved" exact="pulmonary" post="function and decreased viral load in lung, and the"/>
 <result pre="SARS-CoV- and MERS-CoV-infected mice. NHC improved pulmonary function and decreased" exact="viral" post="load in lung, and the authors proposed that NHC"/>
 <result pre="used for the treatment of patients chronically infected by the" exact="hepatitis C" post="virus (HCV) (PubChem, 2005c). The antiviral activities of ribavirin"/>
 <result pre="&amp;gt; 200 Î¼g mLâˆ’1) (Saijo et al., 2005). Nevertheless, no" exact="viral" post="load reduction was observed in vivo when employing BALB/c"/>
 <result pre="et al., 2014), and the combined treatment of ribavirin with" exact="type I" post="Interferons (IFN-I) in primate models improved MERS disease symptoms"/>
 <result pre="with type I Interferons (IFN-I) in primate models improved MERS" exact="disease" post="symptoms (Falzarano et al., 2013b). Although ribavirin has been"/>
 <result pre="and MERS patients, meta-analyses of cases of study have found" exact="limited" post="efficacy of its activities in treating patients with highly"/>
 <result pre="of its activities in treating patients with highly pathogenic coronavirus" exact="respiratory" post="syndromes (Morra et al., 2018). What is more, a"/>
 <result pre="authors did not suggest mechanisms by which this analog impairs" exact="viral" post="replication, leaving open to question whether it acts like"/>
 <result pre="to question whether it acts like its precursor acyclovir, impairing" exact="viral" post="replication or by an alternative mechanism of action. In"/>
 <result pre="of other drug options for the post-entry stages of the" exact="viral" post="replicative cycle, it is possible to report the activities"/>
 <result pre="1977). Niclosamide presented antiviral activity on post-entry steps of SARS-CoV" exact="infection" post="in Vero cells, with an EC50 of 1â€&quot;3 Î¼M"/>
 <result pre="effect of SARS-CoV at a concentration &amp;lt;1 Î¼M and inhibited" exact="viral" post="replication with an EC50 value of less than 0.1"/>
 <result pre="cellular immune responses that are important for preventing or limiting" exact="viral infection" post="(Barnard et al., 2006). Bananins, on the other hand,"/>
 <result pre="immune responses that are important for preventing or limiting viral" exact="infection" post="(Barnard et al., 2006). Bananins, on the other hand,"/>
 <result pre="MHV infected mice and demonstrated that treatment improved survival, decreased" exact="viral" post="load in liver, and induced type 1 IFN. Based"/>
 <result pre="treatment improved survival, decreased viral load in liver, and induced" exact="type 1" post="IFN. Based on these data, it was suggested that"/>
 <result pre="Different Approach to CoV Treatment Targeting the host process during" exact="viral infection" post="figures as a promising alternative for drug development and"/>
 <result pre="Approach to CoV Treatment Targeting the host process during viral" exact="infection" post="figures as a promising alternative for drug development and"/>
 <result pre="drug development and can play an important role in abrogating" exact="viral" post="replication (Sayce et al., 2010; Ullah et al., 2019)."/>
 <result pre="its activity related to the interference in host-regulated pathways during" exact="viral" post="replication (Rossignol, 2016). In vitro studies demonstrated that Nitazoxanide"/>
 <result pre="strictly related to CoV infection. Therefore, SFK inhibition might promote" exact="viral" post="clearance and can be used in association with other"/>
 <result pre="and it seems to interfere with genome replication/transcription during CoV" exact="infections" post="(de Wilde et al., 2011, 2013; Pfefferle et al.,"/>
 <result pre="have been described as promising candidates for the treatment of" exact="hepatitis" post="B virus (HBV), HCV, HIV, and human T-cell lymphotropic"/>
 <result pre="virus (HBV), HCV, HIV, and human T-cell lymphotropic virus (HTLV)" exact="infections" post="(Ma et al., 2007; Shah and Schaffer, 2011; Sanan-Mishra"/>
 <result pre="al., 2016, 57). Its activity was assessed in human airway" exact="epithelial" post="(HAE) cells infected with SARS-CoV (EC50 of 0.069 Î¼M"/>
 <result pre="demonstrated to inhibit RdRp of these viruses. Also, GS-5734 reduced" exact="infectious" post="virus production of bat CoV by 1.5 to 2.0"/>
 <result pre="which are protease inhibitors used in association to treat HIV" exact="infections" post="(Cvetkovic and Goa, 2003; Mills et al., 2009). Lopinavir"/>
 <result pre="al., 2009). Lopinavir demonstrated antiviral activities, protecting cells from MERS-CoV" exact="infection" post="(EC50 of 8 Î¼M) and reducing viral loads in"/>
 <result pre="cells from MERS-CoV infection (EC50 of 8 Î¼M) and reducing" exact="viral" post="loads in animal assays (de Wilde et al., 2014;"/>
 <result pre="association of Lopinavir with Ritonavir reduced adverse clinical outcomes and" exact="viral" post="load in infected patients (Sheahan et al., 2020a; Yao"/>
 <result pre="the association Lopinavir/Ritonavir did not improve symptoms, nor impaired detectable" exact="viral" post="RNA when compared to standard care (supplemental oxygen, noninvasive"/>
 <result pre="since individuals that were treated at the onset of the" exact="disease" post="had improved clinical results (Cao et al., 2020b). Later,"/>
 <result pre="moderate COVID-19 patients alleviated symptoms and decreased the durations of" exact="viral infection" post="and hospital stay (Hung et al., 2020). This might"/>
 <result pre="COVID-19 patients alleviated symptoms and decreased the durations of viral" exact="infection" post="and hospital stay (Hung et al., 2020). This might"/>
 <result pre="to their inducing cellular immune response, impairing virus replication. The" exact="type 1" post="interferons (IFN-I) have also been employed in clinical trials."/>
 <result pre="cytokine family and are associated with the immune response in" exact="viral" post="infections, thus playing major roles in antiviral immunity due"/>
 <result pre="commonly employed in the treatment of several diseases such as" exact="Hepatitis" post="C (Kobayashi et al., 1993). There are two subtypes"/>
 <result pre="2015) and is therefore capitalized on in the treatment for" exact="multiple sclerosis" post="patients (Axtell et al., 2010). Due to its more"/>
 <result pre="However, it did not impair mortality in patients with no" exact="respiratory" post="support (Horby et al., 2020). Other trials have been"/>
 <result pre="third phase of COVID-19, when the hyperinflammation is determined, and" exact="respiratory" post="support is needed. Another antiviral drug assayed toward SARS-CoV-2"/>
 <result pre="observational study with 81 patients with moderate to severe SARS-CoV-2" exact="infection" post="(Lian et al., 2020) that demonstrated that Umifenovir neither"/>
 <result pre="patients (Lian et al., 2020). Broad-spectrum drugs used against parasitic" exact="infections" post="such as Ivermectin (Campbell, 2012; Laing et al., 2017)"/>
 <result pre="have also been investigated due to their antiviral activity against" exact="Dengue" post="virus (DENV), Influenza A viruses, Chikungunya virus (CHIKV), and"/>
 <result pre="activity of Ivermectin is based on impairing several stages of" exact="viral" post="replication, for instance, interfering with nonstructural proteins (Varghese et"/>
 <result pre="no toxicity to cells and inhibited up to 99% of" exact="viral" post="replication by a possible antiviral effect on viral release,"/>
 <result pre="99% of viral replication by a possible antiviral effect on" exact="viral" post="release, which is consistent with previous data on its"/>
 <result pre="colleagues, approximately 15.7% of Chinese patients with COVID-19 developed severe" exact="pneumonia" post="and cytokine release syndrome (CRS), an important factor leading"/>
 <result pre="Chinese patients with COVID-19 developed severe pneumonia and cytokine release" exact="syndrome" post="(CRS), an important factor leading to rapid progression of"/>
 <result pre="(CRS), an important factor leading to rapid progression of the" exact="disease" post="(Chousterman et al., 2017; Guan et al., 2020). In"/>
 <result pre="of 62 years old) who had been diagnosed with COVID-19" exact="pneumonia" post="and ARDS and required ventilatory support. Overall, at 10"/>
 <result pre="required ventilatory support. Overall, at 10 days of follow-up, the" exact="respiratory" post="condition was improved or stabilized in 77% of the"/>
 <result pre="2017). Chloroquine was described as an entry inhibitor of SARS-CoV" exact="infection" post="in Vero cells and prevented cell-to-cell spread of the"/>
 <result pre="collaborators indicated that chloroquine phosphate was recommended to treat COVID-19-associated" exact="pneumonia" post="only during urgent clinical demand because of its antiviral"/>
 <result pre="pointes (TdP), which is a risk especially for patients with" exact="cardiac disease," post="for children, or for those taking other drugs that"/>
 <result pre="paranoia, depression, psychosis, and suicidal ideation (Mohan et al., 1981);" exact="hypersensitivity" post="reactions, such as severe cutaneous adverse reactions (Cameron et"/>
 <result pre="ideation (Mohan et al., 1981); hypersensitivity reactions, such as severe" exact="cutaneous" post="adverse reactions (Cameron et al., 2014; Girijala et al.,"/>
 <result pre="COVID-19, and so doses that proved effective and safe in" exact="malaria" post="for both adults and children are considered for the"/>
 <result pre="of the Solidarity trial to treat COVID-19 based on an" exact="absence of" post="effectiveness in reducing the mortality of hospitalized COVID-19 patients"/>
 <result pre="chloroquine in COVID-19 patients, mainly due to the risk of" exact="heart" post="rhythm issues (FDA, 2020). From these results, it is"/>
 <result pre="This plasma/derivative is, in its turn, transfused into individuals with" exact="acute" post="SARS-CoV-2 infection (Garraud, 2017; Cao and Shi, 2020). Even"/>
 <result pre="is, in its turn, transfused into individuals with acute SARS-CoV-2" exact="infection" post="(Garraud, 2017; Cao and Shi, 2020). Even though the"/>
 <result pre="reported CP transfusion to rescue ten severe cases of SARS-CoV-2" exact="adult" post="patients. The study showed that one dose (200 mL)"/>
 <result pre="well as for a better comprehension of their interactions with" exact="viral" post="biomolecules, has been shown as a promising tool for"/>
 <result pre="described above, these compounds were capable of significantly impairing CoV" exact="infection" post="in cell cultures and might enable important progress into"/>
 <result pre="as well as viruses that might be responsible for future" exact="viral" post="outbreaks. Here, we also described compounds that were evaluated"/>
 <result pre="C57BL/6, to evaluate the antiviral effect of compounds in CoV" exact="infection" post="(Cinatl et al., 2003; Saijo et al., 2005; Barnard"/>
 <result pre="ADMeTox profile of these compounds in complex biological systems, the" exact="viral" post="titers in different organs, host immune responses to the"/>
 <result pre="tissue damage caused by the viruses in the presence or" exact="absence of" post="candidate drugs, which represents an advance in understanding pathologies"/>
 <result pre="drugs, which represents an advance in understanding pathologies caused by" exact="viral" post="infections (Adachi and Miura, 2014). It is also important"/>
 <result pre="which represents an advance in understanding pathologies caused by viral" exact="infections" post="(Adachi and Miura, 2014). It is also important to"/>
 <result pre="classified to different biological safety levels, representing a risk of" exact="infection" post="to scientists (Bayot and King, 2020; CDC, 2020b). Additionally,"/>
 <result pre="what is observed for human-related CoVs, which mostly affect the" exact="upper" post="respiratory system (Pedersen et al., 1984; Coleman and Frieman,"/>
 <result pre="is observed for human-related CoVs, which mostly affect the upper" exact="respiratory" post="system (Pedersen et al., 1984; Coleman and Frieman, 2014)."/>
 <result pre="The development of refined and secure protocols to study SARS-CoV-2" exact="infection" post="and its treatment options is required. Bearing in mind"/>
 <result pre="Saracatinib, Tizoxanide, Nitazoxanide, Niclosamide, and Ribavirin. These compounds abrogated CoV" exact="infection" post="in vitro and in vivo and improved the symptoms"/>
 <result pre="are molecules licensed to treat diseases such as those from" exact="viral" post="and helminthic infections or Alzheimerâ€™s disease, representing possibilities for"/>
 <result pre="to treat diseases such as those from viral and helminthic" exact="infections" post="or Alzheimerâ€™s disease, representing possibilities for clinical trials as"/>
 <result pre="and Umifenovir are drugs employed for the treatment of other" exact="viral" post="infections such as EBOV and SARS-CoV, but, in the"/>
 <result pre="Umifenovir are drugs employed for the treatment of other viral" exact="infections" post="such as EBOV and SARS-CoV, but, in the clinical"/>
 <result pre="COVID-19 patients, these treatments did not reduce symptoms and/or decrease" exact="viral" post="load. Tocilizumab, Chloroquine, and Hydroxychloroquine have been demonstrated to"/>
 <result pre="trials, reduced COVID-19 symptoms, the period of hospitalization, and the" exact="viral" post="load in patients despite the strong adverse effects of"/>
 <result pre="safety profiles of Chloroquine and Hydroxychloroquine, since they might cause" exact="arrhythmia" post="in patients, representing risk for a considerable number of"/>
 <result pre="with other drugs, collaborating to control immune response against the" exact="viral infection" post="(Table 2). On the other hand, corticosteroids, such as"/>
 <result pre="other drugs, collaborating to control immune response against the viral" exact="infection" post="(Table 2). On the other hand, corticosteroids, such as"/>
 <result pre="of B cells for antibody secretion, which are essential for" exact="viral" post="clearance (Cohn, 1991; Giles et al., 2018). Furthermore, convalescent"/>
 <result pre="donors), which might cause severe adverse effects in lung and" exact="cardiovascular" post="system and, in some cases, may even transmit diseases"/>
 <result pre="and different outcomes can be expected in each situation since" exact="viral" post="load, the progression of the disease, and immune response"/>
 <result pre="are not considered, the investigators might be open to commiting" exact="type I" post="or II error in trials (Kernan et al., 1999;"/>
 <result pre="SARS-CoV-2 is a new virus and that we currently have" exact="limited" post="knowledge about its physiopathology. Finally, the development of new"/>
 <result pre="demonstrated that the use of Chloroquine analogs for decades against" exact="malaria" post="has established chloroquine-resistant Plasmodium strains (Stocks et al., 2002;"/>
 <result pre="effects of analogs on the severe inflammatory complications of several" exact="viral" post="diseases, such as HIV and SARS-CoV infections, these drugs"/>
 <result pre="SARS-CoV-2 pandemic might raise concerns regarding the emergence of resistant" exact="viral" post="strains in the future, and we emphasize the lack"/>
 <result pre="the resistance associated with these drugs in the treatment of" exact="viral" post="infections. Conclusion The spread of SARS-CoV-2 worldwide is classified"/>
 <result pre="The authors declare that the research was conducted in the" exact="absence of" post="any commercial or financial relationships that could be construed"/>
 <result pre="(National Counsel of Technological and Scientific Development â€&quot; 311219/2019-5). The" exact="Brazilian" post="funding agencies CNPq, CAPES, and FAPEMIG provide financial support"/>
 <result pre="RS-S, and FB are grateful to CAPES â€&quot; Prevention and" exact="Combat" post="of Outbreaks, Endemics, Epidemics and Pandemics - Finance Code"/>
 <result pre="2020 (https://doi.org/10.31219/osf.io/ycjgq). References References AdachiA.MiuraT. (2014). Animal model studies on" exact="viral" post="infections.Front. Microbiol.5:672. 10.3389/fmicb.2014.0067225520715 AdedejiA. O.SeversonW.JonssonC.SinghK.WeissS. R.SarafianosS. G. (2013). Novel"/>
 <result pre="10.3389/fmicb.2014.0067225520715 AdedejiA. O.SeversonW.JonssonC.SinghK.WeissS. R.SarafianosS. G. (2013). Novel inhibitors of severe" exact="acute" post="respiratory syndrome coronavirus entry that act by three distinct"/>
 <result pre="AdedejiA. O.SeversonW.JonssonC.SinghK.WeissS. R.SarafianosS. G. (2013). Novel inhibitors of severe acute" exact="respiratory" post="syndrome coronavirus entry that act by three distinct mechanisms.J."/>
 <result pre="O.SeversonW.JonssonC.SinghK.WeissS. R.SarafianosS. G. (2013). Novel inhibitors of severe acute respiratory" exact="syndrome" post="coronavirus entry that act by three distinct mechanisms.J. Virol.878017â€&quot;8028."/>
 <result pre="(2014). Evaluation of serologic and antigenic relationships between middle eastern" exact="respiratory" post="syndrome coronavirus and other coronaviruses to develop vaccine platforms"/>
 <result pre="Evaluation of serologic and antigenic relationships between middle eastern respiratory" exact="syndrome" post="coronavirus and other coronaviruses to develop vaccine platforms for"/>
 <result pre="N.et al. (2020). Tocilizumab for the treatment of severe coronavirus" exact="disease" post="2019.J. Med. Virol. Online ahead of print. 10.1002/jmv.2596432369191 Al-BariM."/>
 <result pre="analogs as a promising strategy for the treatment of emerging" exact="viral" post="diseases.Pharmacol. Res. Perspect.51â€&quot;13. 10.1002/prp2.29328596841 Al-TawfiqJ. A.MomattinH.DibJ.MemishZ. A. (2014). Ribavirin"/>
 <result pre="and interferon therapy in patients infected with the Middle East" exact="respiratory" post="syndrome coronavirus: an observational study.Int. J. Infect. Dis.2042â€&quot;46. 10.1016/j.ijid.2013.12.00324406736"/>
 <result pre="interferon therapy in patients infected with the Middle East respiratory" exact="syndrome" post="coronavirus: an observational study.Int. J. Infect. Dis.2042â€&quot;46. 10.1016/j.ijid.2013.12.00324406736 AnandK.ZiebuhrJ.WadhwaniP.MestersJ."/>
 <result pre="JongB. A.BonifaceK.van der VoortL. F.BhatR.De SarnoP.et al. (2010). T helper" exact="type 1" post="and 17 cells determine efficacy of interferon-Î² in multiple"/>
 <result pre="type 1 and 17 cells determine efficacy of interferon-Î² in" exact="multiple sclerosis" post="and experimental encephalomyelitis.Nat. Med.16406â€&quot;412. 10.1038/nm.211020348925 BalasubramaniamM.ReisR. J. S. (2020)."/>
 <result pre="L.HubbardV. D.BurtonJ.SmeeD. F.MorreyJ. D.OttoM. J.et al. (2004). Inhibition of severe" exact="acute" post="respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-D-N4-hydroxycytidine.Antivir."/>
 <result pre="D.BurtonJ.SmeeD. F.MorreyJ. D.OttoM. J.et al. (2004). Inhibition of severe acute" exact="respiratory" post="syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-D-N4-hydroxycytidine.Antivir. Chem."/>
 <result pre="of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on" exact="acute" post="respiratory distress syndrome mortality: an open-label study.Lancet Respir. Med.298â€&quot;107."/>
 <result pre="intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute" exact="respiratory" post="distress syndrome mortality: an open-label study.Lancet Respir. Med.298â€&quot;107. 10.1016/S2213-2600(13)70259-524503265"/>
 <result pre="(FP-1201) on lung CD73 expression and on acute respiratory distress" exact="syndrome" post="mortality: an open-label study.Lancet Respir. Med.298â€&quot;107. 10.1016/S2213-2600(13)70259-524503265 BelouzardS.ChuV. C.WhittakerG."/>
 <result pre="R. (2012). Mechanisms of coronavirus cell entry mediated by the" exact="viral" post="spike protein.Viruses41011â€&quot;1033. 10.3390/v406101122816037 CalyL.DruceJ. D.CattonM. G.JansD. A.WagstaffK. M. (2020)."/>
 <result pre="in vitro.Antiviral Res.178:104787. 10.1016/j.antiviral.2020.10478732251768 CameronM. C.WordA. P.DominguezA. (2014). Hydroxychloroquine-induced fatal" exact="toxic epidermal necrolysis" post="complicated by angioinvasive rhizopus.Dermatol. Online J.20:13030/qt1q90q0h5. CampbellW. C. (2012)."/>
 <result pre="Media. CaoH.ShiY. (2020). Convalescent plasma: possible therapy for novel coronavirus" exact="disease" post="2019.Transfusion601078â€&quot;1083. 10.1111/trf.1579732359090 CaoY.LiL.FengZ.WanS.HuangP.SunX.et al. (2020a). Comparative genetic analysis of"/>
 <result pre="12, 2020) CeccarelliM.BerrettaM.RulloE. V.NunnariG.CacopardoB. (2020). Differences and similarities between severe" exact="acute" post="respiratory syndrome (SARS)-CoronaVirus (CoV) and SARS-CoV-2. Would a rose"/>
 <result pre="2020) CeccarelliM.BerrettaM.RulloE. V.NunnariG.CacopardoB. (2020). Differences and similarities between severe acute" exact="respiratory" post="syndrome (SARS)-CoronaVirus (CoV) and SARS-CoV-2. Would a rose by"/>
 <result pre="CeccarelliM.BerrettaM.RulloE. V.NunnariG.CacopardoB. (2020). Differences and similarities between severe acute respiratory" exact="syndrome" post="(SARS)-CoronaVirus (CoV) and SARS-CoV-2. Would a rose by another"/>
 <result pre="Y.et al. (2013). Broad-spectrum antivirals for the emerging middle east" exact="respiratory" post="syndrome coronavirus.J. Infect.67606â€&quot;616. 10.1016/j.jinf.2013.09.02924096239 ChanJ. F.-W.YaoY.YeungM.-L.DengW.BaoL.JiaL.et al. (2015). Treatment"/>
 <result pre="al. (2013). Broad-spectrum antivirals for the emerging middle east respiratory" exact="syndrome" post="coronavirus.J. Infect.67606â€&quot;616. 10.1016/j.jinf.2013.09.02924096239 ChanJ. F.-W.YaoY.YeungM.-L.DengW.BaoL.JiaL.et al. (2015). Treatment with"/>
 <result pre="(2015). Treatment with lopinavir/ritonavir or interferon-Î²1b improves outcome of MERS-CoV" exact="infection" post="in a nonhuman primate model of common marmoset.J. Infect."/>
 <result pre="R. (2005). Overview of antiviral and anti-inflammatory treatment for severe" exact="acute" post="respi ratory syndrome.Expert Rev. Anti Infect. Ther.3251â€&quot;262. 10.1586/14787210.3.2.25115918782 ChorinE.DaiM.ShulmanE.WadhwaniL.CohenR."/>
 <result pre="B.BarbhaiyaC.et al. (2020). The QT Interval in Patients with SARS-CoV-2" exact="Infection" post="Treated with Hydroxychloroquine/Azithromycin.medRxiv [Preprint]10.1101/2020.04.02.20047050 ChoustermanB. G.SwirskiF. K.WeberG. F. (2017)."/>
 <result pre="[Preprint]10.1101/2020.04.02.20047050 ChoustermanB. G.SwirskiF. K.WeberG. F. (2017). Cytokine storm and sepsis" exact="disease" post="pathogenesis.Semin. Immunopathol.39517â€&quot;528. 10.1007/s00281-017-0639-828555385 ChuC. M.ChengV. C. C.HungI. F. N.WongM."/>
 <result pre="10.1016/S2666-5247(20)30004-5 CinatlJ.MichaelisM.HoeverG.PreiserW.DoerrH. W. (2005). Development of antiviral therapy for severe" exact="acute" post="respiratory syndrome.Antiviral Res.6681â€&quot;97. 10.1016/j.antiviral.2005.03.00215878786 CinatlJ.MorgensternB.BauerG.ChandraP.RabenauH.DoerrH. W. (2003). Glycyrrhizin, an"/>
 <result pre="CinatlJ.MichaelisM.HoeverG.PreiserW.DoerrH. W. (2005). Development of antiviral therapy for severe acute" exact="respiratory" post="syndrome.Antiviral Res.6681â€&quot;97. 10.1016/j.antiviral.2005.03.00215878786 CinatlJ.MorgensternB.BauerG.ChandraP.RabenauH.DoerrH. W. (2003). Glycyrrhizin, an active"/>
 <result pre="lychas mucronatus.Antimicrob. Agents Chemother.523967â€&quot;3972. 10.1128/AAC.00542-0818779362 Dâ€™AmatoG.StanziolaA.SanduzziA.LiccardiG.SalzilloA.VitaleC.et al. (2014). Treating severe" exact="allergic asthma" post="with anti-IgE monoclonal antibody (omalizumab): a review.Multidiscip. Respir. Med.9:23."/>
 <result pre="mucronatus.Antimicrob. Agents Chemother.523967â€&quot;3972. 10.1128/AAC.00542-0818779362 Dâ€™AmatoG.StanziolaA.SanduzziA.LiccardiG.SalzilloA.VitaleC.et al. (2014). Treating severe allergic" exact="asthma" post="with anti-IgE monoclonal antibody (omalizumab): a review.Multidiscip. Respir. Med.9:23."/>
 <result pre="review.Multidiscip. Respir. Med.9:23. 10.1186/2049-6958-9-2324735949 DavisT. L.WalkerJ. R.Campagna-SlaterV.FinertyP. J.ParamanathanR.BernsteinG.et al. (2010)." exact="Structural" post="and biochemical characterization of the human cyclophilin family of"/>
 <result pre="MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus" exact="infection" post="in a mouse model.Virus Res.2287â€&quot;13. 10.1016/j.virusres.2016.11.01127840112 de WildeA. H.JochmansD.PosthumaC."/>
 <result pre="FDA-approved compound library identifies four small-molecule inhibitors of middle east" exact="respiratory" post="syndrome coronavirus replication in cell culture.Antimicrob. Agents Chemother.584875â€&quot;4884. 10.1128/AAC.03011-1424841269"/>
 <result pre="compound library identifies four small-molecule inhibitors of middle east respiratory" exact="syndrome" post="coronavirus replication in cell culture.Antimicrob. Agents Chemother.584875â€&quot;4884. 10.1128/AAC.03011-1424841269 de"/>
 <result pre="patients.Proc. Natl. Acad. Sci. U.S.A.1179490â€&quot;9496. 10.1073/pnas.200416811732253318 El-SoliaA.Al-OtaibiK.Ai-HwieshA. K. (2018). Hydroxychloroquine-induced" exact="hypoglycaemia" post="in non-diabetic renal patient on peritoneal dialysis.BMJ Case Rep.2018:bcr2017223639."/>
 <result pre="Hospital Setting or a Clinical trial due to Risk of" exact="Heart" post="Rhythm Problems. Available online at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or(accessed July 5, 2020)"/>
 <result pre="NJ12821â€&quot;23. 10.1007/978-1-4939-2438-7_125870870 FerronF.SubissiL.De MoraisA. T. S.LeN. T. T.SevajolM.GluaisL.et al. (2017)." exact="Structural" post="and molecular basis of mismatch correction and ribavirin excision"/>
 <result pre="RNA polymerases and their emerging roles in antiviral therapy,â€� in" exact="Viral" post="Polymerases, ed.GuptaS. P. (Cambridge, MA: Academic Press), 1â€&quot;42. 10.1016/B978-0-12-815422-9.00001-2"/>
 <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studies.Biosci. Trends1472â€&quot;73. 10.5582/BST.2020.0104732074550 GarraudO. (2017). Use of"/>
 <result pre="immunotherapy.J. Immunother. Cancer6:51. 10.1186/s40425-018-0371-529891009 GirijalaR. L.SiddiqiI.KwakY.WrightD.PatelD. B.GoldbergL. H. (2019). Pustular" exact="DRESS syndrome" post="secondary to hydroxychloroquine with EBV reactivation.J. Drugs Dermatol. JDD18207â€&quot;209.30811149"/>
 <result pre="Immunother. Cancer6:51. 10.1186/s40425-018-0371-529891009 GirijalaR. L.SiddiqiI.KwakY.WrightD.PatelD. B.GoldbergL. H. (2019). Pustular DRESS" exact="syndrome" post="secondary to hydroxychloroquine with EBV reactivation.J. Drugs Dermatol. JDD18207â€&quot;209.30811149"/>
 <result pre="Cancer6:51. 10.1186/s40425-018-0371-529891009 GirijalaR. L.SiddiqiI.KwakY.WrightD.PatelD. B.GoldbergL. H. (2019). Pustular DRESS syndrome" exact="secondary" post="to hydroxychloroquine with EBV reactivation.J. Drugs Dermatol. JDD18207â€&quot;209.30811149 GorbalenyaA."/>
 <result pre="JDD18207â€&quot;209.30811149 GorbalenyaA. E.BakerS. C.BaricR. S.de GrootR. J.DrostenC.GulyaevaA. A.et al. (2020a)." exact="Severe" post="acute respiratory syndrome-related coronavirus: the species and its viruses"/>
 <result pre="GorbalenyaA. E.BakerS. C.BaricR. S.de GrootR. J.DrostenC.GulyaevaA. A.et al. (2020a). Severe" exact="acute" post="respiratory syndrome-related coronavirus: the species and its viruses â€&quot;"/>
 <result pre="E.BakerS. C.BaricR. S.de GrootR. J.DrostenC.GulyaevaA. A.et al. (2020a). Severe acute" exact="respiratory" post="syndrome-related coronavirus: the species and its viruses â€&quot; a"/>
 <result pre="E.BakerS. C.BaricR. S.de GrootR. J.DrostenC.GulyaevaA. A.et al. (2020b). The species" exact="Severe" post="acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it"/>
 <result pre="C.BaricR. S.de GrootR. J.DrostenC.GulyaevaA. A.et al. (2020b). The species Severe" exact="acute" post="respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2.Nat."/>
 <result pre="S.de GrootR. J.DrostenC.GulyaevaA. A.et al. (2020b). The species Severe acute" exact="respiratory" post="syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2.Nat. Microbiol.5536â€&quot;544."/>
 <result pre="L.RheingoldS. R.et al. (2013). Chimeric antigen receptorâ€&quot;modified T cells for" exact="acute" post="lymphoid leukemia.N. Engl. J. Med.3681509â€&quot;1518. 10.1056/NEJMoa121513423527958 GuanB.-J.SuY.-P.WuH.-Y.BrianD. A. (2012)."/>
 <result pre="Coronaviruses.J. Virol.864631â€&quot;4643. 10.1128/JVI.06265-1122345457 GuanW.NiZ.HuY.LiangW.OuC.HeJ.et al. (2020). Clinical characteristics of Coronavirus" exact="disease" post="2019 in China.N. Engl. J. Med.3821708â€&quot;1720. 10.1056/NEJMoa200203232109013 HagaS.NagataN.OkamuraT.YamamotoN.SataT.YamamotoN.et al."/>
 <result pre="protein of SARS-CoV and ACE2 induces TNF- production and facilitates" exact="viral" post="entry.Proc. Natl. Acad. Sci. U.S.A.1057809â€&quot;7814. 10.1073/pnas.071124110518490652 HanD. P.LohaniM.ChoM. W."/>
 <result pre="asparagine-linked glycosylation sites are critical for DC-SIGN- and L-SIGN-mediated severe" exact="acute" post="respiratory syndrome Coronavirus entry.J. Virol.8112029â€&quot;12039. 10.1128/JVI.00315-0717715238 HartB. J.DyallJ.PostnikovaE.ZhouH.KindrachukJ.JohnsonR. F.et"/>
 <result pre="glycosylation sites are critical for DC-SIGN- and L-SIGN-mediated severe acute" exact="respiratory" post="syndrome Coronavirus entry.J. Virol.8112029â€&quot;12039. 10.1128/JVI.00315-0717715238 HartB. J.DyallJ.PostnikovaE.ZhouH.KindrachukJ.JohnsonR. F.et al."/>
 <result pre="sites are critical for DC-SIGN- and L-SIGN-mediated severe acute respiratory" exact="syndrome" post="Coronavirus entry.J. Virol.8112029â€&quot;12039. 10.1128/JVI.00315-0717715238 HartB. J.DyallJ.PostnikovaE.ZhouH.KindrachukJ.JohnsonR. F.et al. (2014)."/>
 <result pre="Interferon-Î² and mycophenolic acid are potent inhibitors of middle east" exact="respiratory" post="syndrome coronavirus in cell-based assays.J. Gen. Virol.95571â€&quot;577. 10.1099/vir.0.061911-024323636 HaynesL."/>
 <result pre="and mycophenolic acid are potent inhibitors of middle east respiratory" exact="syndrome" post="coronavirus in cell-based assays.J. Gen. Virol.95571â€&quot;577. 10.1099/vir.0.061911-024323636 HaynesL. M.CaidiH.RaduG."/>
 <result pre="U.MiaoC.HarcourtJ. L.TrippR. A.et al. (2009). Therapeutic monoclonal antibody treatment targeting" exact="respiratory" post="syncytial virus (RSV) G protein mediates viral clearance and"/>
 <result pre="antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates" exact="viral" post="clearance and reduces the pathogenesis of RSV infection in"/>
 <result pre="protein mediates viral clearance and reduces the pathogenesis of RSV" exact="infection" post="in BALB/c mice.J. Infect. Dis.200439â€&quot;447. 10.1086/60010819545210 HensleyL. E.FritzE. A.JahrlingP."/>
 <result pre="J.et al. (2004). CD209L (L-SIGN) is a receptor for severe" exact="acute" post="respiratory syndrome coronavirus.Proc. Natl. Acad. Sci. U.S.A.10115748â€&quot;15753. 10.1073/pnas.040381210115496474 JeonS.KoM.LeeJ.ChoiI.ByunS."/>
 <result pre="al. (2004). CD209L (L-SIGN) is a receptor for severe acute" exact="respiratory" post="syndrome coronavirus.Proc. Natl. Acad. Sci. U.S.A.10115748â€&quot;15753. 10.1073/pnas.040381210115496474 JeonS.KoM.LeeJ.ChoiI.ByunS. Y.ParkS.et"/>
 <result pre="(2004). CD209L (L-SIGN) is a receptor for severe acute respiratory" exact="syndrome" post="coronavirus.Proc. Natl. Acad. Sci. U.S.A.10115748â€&quot;15753. 10.1073/pnas.040381210115496474 JeonS.KoM.LeeJ.ChoiI.ByunS. Y.ParkS.et al."/>
 <result pre="A new lead for nonpeptidic active-site-directed inhibitors of the severe" exact="acute" post="respiratory syndrome coronavirus main protease discovered by a combination"/>
 <result pre="new lead for nonpeptidic active-site-directed inhibitors of the severe acute" exact="respiratory" post="syndrome coronavirus main protease discovered by a combination of"/>
 <result pre="lead for nonpeptidic active-site-directed inhibitors of the severe acute respiratory" exact="syndrome" post="coronavirus main protease discovered by a combination of screening"/>
 <result pre="of Arbidol and its Derivatives against the Pathogen of severe" exact="Acute" post="Respiratory Syndrome in the Cell Cultures.9â€&quot;13. Available online at:"/>
 <result pre="Arbidol and its Derivatives against the Pathogen of severe Acute" exact="Respiratory" post="Syndrome in the Cell Cultures.9â€&quot;13. Available online at: https://europepmc.org/article/med/18756809(accessed"/>
 <result pre="and its Derivatives against the Pathogen of severe Acute Respiratory" exact="Syndrome" post="in the Cell Cultures.9â€&quot;13. Available online at: https://europepmc.org/article/med/18756809(accessed June"/>
 <result pre="Combination therapy with lopinavir/ritonavir, ribavirin and interferon-Î± for Middle East" exact="respiratory" post="syndrome: a case report.Antivir. Ther.21455â€&quot;459. 10.3851/IMP300226492219 KiparA.MeliM. L.BaptisteK. E.BowkerL."/>
 <result pre="(2018). Challenges of convalescent plasma infusion therapy in Middle East" exact="respiratory" post="Coronavirus infection: a single centre experience.Antivir. Ther.23617â€&quot;622. 10.3851/IMP324329923831 KobayashiY.WatanabeS.KonishiM.YokoiM.KakehashiR.KaitoM.et"/>
 <result pre="experience.Antivir. Ther.23617â€&quot;622. 10.3851/IMP324329923831 KobayashiY.WatanabeS.KonishiM.YokoiM.KakehashiR.KaitoM.et al. (1993). Quantitation and typing of" exact="serum hepatitis" post="C virus RNA in patients with chronic hepatitis C"/>
 <result pre="Ther.23617â€&quot;622. 10.3851/IMP324329923831 KobayashiY.WatanabeS.KonishiM.YokoiM.KakehashiR.KaitoM.et al. (1993). Quantitation and typing of serum" exact="hepatitis C" post="virus RNA in patients with chronic hepatitis C treated"/>
 <result pre="typing of serum hepatitis C virus RNA in patients with" exact="chronic hepatitis C" post="treated with interferon-Î².Hepatology181319â€&quot;1325. 10.1002/hep.18401806068244255 LaiC.-C.ShihT.-P.KoW.-C.TangH.-J.HsuehP.-R. (2020). Severe acute respiratory"/>
 <result pre="of serum hepatitis C virus RNA in patients with chronic" exact="hepatitis C" post="treated with interferon-Î².Hepatology181319â€&quot;1325. 10.1002/hep.18401806068244255 LaiC.-C.ShihT.-P.KoW.-C.TangH.-J.HsuehP.-R. (2020). Severe acute respiratory"/>
 <result pre="with chronic hepatitis C treated with interferon-Î².Hepatology181319â€&quot;1325. 10.1002/hep.18401806068244255 LaiC.-C.ShihT.-P.KoW.-C.TangH.-J.HsuehP.-R. (2020)." exact="Severe" post="acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019"/>
 <result pre="chronic hepatitis C treated with interferon-Î².Hepatology181319â€&quot;1325. 10.1002/hep.18401806068244255 LaiC.-C.ShihT.-P.KoW.-C.TangH.-J.HsuehP.-R. (2020). Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19):"/>
 <result pre="hepatitis C treated with interferon-Î².Hepatology181319â€&quot;1325. 10.1002/hep.18401806068244255 LaiC.-C.ShihT.-P.KoW.-C.TangH.-J.HsuehP.-R. (2020). Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the"/>
 <result pre="C treated with interferon-Î².Hepatology181319â€&quot;1325. 10.1002/hep.18401806068244255 LaiC.-C.ShihT.-P.KoW.-C.TangH.-J.HsuehP.-R. (2020). Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic"/>
 <result pre="M.StohlmanS. A. (1981). Comparative analysis of RNA genomes of mouse" exact="hepatitis" post="viruses.J. Virol.38661â€&quot;670. 10.1128/jvi.38.2.661-670.19816165837 LaingR.GillanV.DevaneyE. (2017). Ivermectin â€&quot; old drug."/>
 <result pre="cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with" exact="systemic" post="lupus erythematosus.Arthritis Rheumatol.68184â€&quot;190. 10.1002/art.3940226316040 LeeT.-W.CherneyM. M.HuitemaC.LiuJ.JamesK. E.PowersJ. C.et al."/>
 <result pre="P450 2D6 with blood hydroxychloroquine levels in patients with systemic" exact="lupus" post="erythematosus.Arthritis Rheumatol.68184â€&quot;190. 10.1002/art.3940226316040 LeeT.-W.CherneyM. M.HuitemaC.LiuJ.JamesK. E.PowersJ. C.et al. (2005)."/>
 <result pre="(2019). Overview of direct-acting antiviral drugs and drug resistance of" exact="hepatitis C" post="Virus.Methods Mol. Biol. Clifton NJ19113â€&quot;32. 10.1007/978-1-4939-8976-8_1 LiK.LiH.BiZ.SongD.ZhangF.LeiD.et al. (2019)."/>
 <result pre="is not associated with improved outcomes in patients with coronavirus" exact="disease" post="2019: a retrospective study.Clin. Microbiol. Infect.26917â€&quot;921. 10.1016/j.cmi.2020.04.02632344167 LipK.-M.ShenS.YangX.KengC.-T.ZhangA.OhH.-L. J.et"/>
 <result pre="of the HR2 of the S protein neutralize in vitro" exact="infection" post="of severe acute respiratory syndrome coronavirus.J. Virol.80941â€&quot;950. 10.1128/JVI.80.2.941-950.200616378996 LipinskiC."/>
 <result pre="of the S protein neutralize in vitro infection of severe" exact="acute" post="respiratory syndrome coronavirus.J. Virol.80941â€&quot;950. 10.1128/JVI.80.2.941-950.200616378996 LipinskiC. A.LombardoF.DominyB. W.FeeneyP. J."/>
 <result pre="the S protein neutralize in vitro infection of severe acute" exact="respiratory" post="syndrome coronavirus.J. Virol.80941â€&quot;950. 10.1128/JVI.80.2.941-950.200616378996 LipinskiC. A.LombardoF.DominyB. W.FeeneyP. J. (2001)."/>
 <result pre="S protein neutralize in vitro infection of severe acute respiratory" exact="syndrome" post="coronavirus.J. Virol.80941â€&quot;950. 10.1128/JVI.80.2.941-950.200616378996 LipinskiC. A.LombardoF.DominyB. W.FeeneyP. J. (2001). Experimental"/>
 <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitro.Cell Discov.61â€&quot;4. 10.1038/s41421-020-0156-031934347 LuG.WangQ.GaoG. F. (2015). Bat-to-human: spike"/>
 <result pre="interference and antiviral therapy.World J. Gastroenterol.135169â€&quot;5179. 10.3748/wjg.v13.i39.516917876887 MadhugiriR.KarlN.PetersenD.LamkiewiczK.FrickeM.WendU.et al. (2018)." exact="Structural" post="and functional conservation of cis-acting RNA elements in coronavirus"/>
 <result pre="10.1016/S0140-6736(20)30628-0 MilletJ. K.SÃ©ronK.LabittR. N.DanneelsA.PalmerK. E.WhittakerG. R.et al. (2016). Middle East" exact="respiratory" post="syndrome coronavirus infection is inhibited by griffithsin.Antiviral Res.1331â€&quot;8. 10.1016/j.antiviral.2016.07.01127424494"/>
 <result pre="MilletJ. K.SÃ©ronK.LabittR. N.DanneelsA.PalmerK. E.WhittakerG. R.et al. (2016). Middle East respiratory" exact="syndrome" post="coronavirus infection is inhibited by griffithsin.Antiviral Res.1331â€&quot;8. 10.1016/j.antiviral.2016.07.01127424494 MillsA."/>
 <result pre="N.DanneelsA.PalmerK. E.WhittakerG. R.et al. (2016). Middle East respiratory syndrome coronavirus" exact="infection" post="is inhibited by griffithsin.Antiviral Res.1331â€&quot;8. 10.1016/j.antiviral.2016.07.01127424494 MillsA. M.NelsonM.JayaweeraD.RuxrungthamK.CassettiI.GirardP.-M.et al."/>
 <result pre="(2018). Clinical outcomes of current medical approaches for Middle East" exact="respiratory" post="syndrome: a systematic review and meta-analysis.Rev. Med. Virol.28:e1977. 10.1002/rmv.197729664167"/>
 <result pre="Dis.6:ofz330. 10.1093/ofid/ofz33031660328 ParrisG. E. (2004). Hypothesis links emergence of chloroquine-resistant" exact="malaria" post="and other intracellular pathogens and suggests a new strategy"/>
 <result pre="10.1016/j.bmcl.2015.05.03926048809 PettittJ.ZeitlinL.KimD. H.WorkingC.JohnsonJ. C.BohorovO.et al. (2013). Therapeutic intervention of ebola" exact="virus infection" post="in rhesus macaques with the MB-003 monoclonal antibody cocktail.Sci."/>
 <result pre="PettittJ.ZeitlinL.KimD. H.WorkingC.JohnsonJ. C.BohorovO.et al. (2013). Therapeutic intervention of ebola virus" exact="infection" post="in rhesus macaques with the MB-003 monoclonal antibody cocktail.Sci."/>
 <result pre="PyrcK.BoschB. J.BerkhoutB.JebbinkM. F.DijkmanR.RottierP.et al. (2006). Inhibition of human coronavirus NL63" exact="infection" post="at early stages of the replication cycle.Antimicrob. Agents Chemother.502000â€&quot;2008."/>
 <result pre="A.Al ZoubiM. S.KasasbehG. A.SalamehD. M.Al-NasserA. D. (2020). SARS-CoV-2 and Coronavirus" exact="disease" post="2019: what we know so far.Pathog. Basel Switz.9:231. 10.3390/pathogens903023132245083"/>
 <result pre="9 - phytotherapy for the liver,â€� in Dietary Interventions in" exact="Liver Disease," post="edsWatsonR. R.PreedyV. R. (Cambridge, MA: Academic Press), 101â€&quot;121. 10.1016/B978-0-12-814466-4.00009-4"/>
 <result pre="free from mechanical ventilation among patients with moderate to severe" exact="acute" post="respiratory distress syndrome: a randomized clinical trial.JAMA323725â€&quot;733. 10.1001/jama.2019.2252532065831 RegueraJ.SantiagoC.MudgalG.OrdoÃ±oD.EnjuanesL.CasasnovasJ."/>
 <result pre="from mechanical ventilation among patients with moderate to severe acute" exact="respiratory" post="distress syndrome: a randomized clinical trial.JAMA323725â€&quot;733. 10.1001/jama.2019.2252532065831 RegueraJ.SantiagoC.MudgalG.OrdoÃ±oD.EnjuanesL.CasasnovasJ. M."/>
 <result pre="distress syndrome: a randomized clinical trial.JAMA323725â€&quot;733. 10.1001/jama.2019.2252532065831 RegueraJ.SantiagoC.MudgalG.OrdoÃ±oD.EnjuanesL.CasasnovasJ. M. (2012)." exact="Structural" post="bases of coronavirus attachment to host aminopeptidase n and"/>
 <result pre="RoquesP.ThibervilleS.-D.Dupuis-MaguiragaL.LumF.-M.LabadieK.MartinonF.et al. (2018). Paradoxical effect of chloroquine treatment in enhancing" exact="chikungunya" post="virus infection.Viruses10:268. 10.3390/v1005026829772762 RossignolJ.-F. (2014). Nitazoxanide: a first-in-class broad-spectrum"/>
 <result pre="a new drug candidate for the treatment of Middle East" exact="respiratory" post="syndrome coronavirus.J. Infect. Public Health9227â€&quot;230. 10.1016/j.jiph.2016.04.00127095301 Ruiz-IrastorzaG.Ramos-CasalsM.Brito-ZeronP.KhamashtaM. A. (2010)."/>
 <result pre="new drug candidate for the treatment of Middle East respiratory" exact="syndrome" post="coronavirus.J. Infect. Public Health9227â€&quot;230. 10.1016/j.jiph.2016.04.00127095301 Ruiz-IrastorzaG.Ramos-CasalsM.Brito-ZeronP.KhamashtaM. A. (2010). Clinical"/>
 <result pre="A. (2010). Clinical efficacy and side effects of antimalarials in" exact="systemic" post="lupus erythematosus: a systematic review.Ann. Rheum. Dis.6920â€&quot;28. 10.1136/ard.2008.10176619103632 SaijoM.MorikawaS.FukushiS.MizutaniT.HasegawaH.NagataN.et"/>
 <result pre="(2010). Clinical efficacy and side effects of antimalarials in systemic" exact="lupus" post="erythematosus: a systematic review.Ann. Rheum. Dis.6920â€&quot;28. 10.1136/ard.2008.10176619103632 SaijoM.MorikawaS.FukushiS.MizutaniT.HasegawaH.NagataN.et al."/>
 <result pre="effect of mizoribine and ribavirin on the replication of severe" exact="acute" post="respiratory syndrome (SARS)-associated coronavirus.Antiviral Res.66159â€&quot;163. 10.1016/j.antiviral.2005.01.00315911031 SallardE.LescureF.-X.YazdanpanahY.MentreF.Peiffer-SmadjaN. (2020). Type"/>
 <result pre="of mizoribine and ribavirin on the replication of severe acute" exact="respiratory" post="syndrome (SARS)-associated coronavirus.Antiviral Res.66159â€&quot;163. 10.1016/j.antiviral.2005.01.00315911031 SallardE.LescureF.-X.YazdanpanahY.MentreF.Peiffer-SmadjaN. (2020). Type 1"/>
 <result pre="mizoribine and ribavirin on the replication of severe acute respiratory" exact="syndrome" post="(SARS)-associated coronavirus.Antiviral Res.66159â€&quot;163. 10.1016/j.antiviral.2005.01.00315911031 SallardE.LescureF.-X.YazdanpanahY.MentreF.Peiffer-SmadjaN. (2020). Type 1 interferons"/>
 <result pre="severe acute respiratory syndrome (SARS)-associated coronavirus.Antiviral Res.66159â€&quot;163. 10.1016/j.antiviral.2005.01.00315911031 SallardE.LescureF.-X.YazdanpanahY.MentreF.Peiffer-SmadjaN. (2020)." exact="Type 1" post="interferons as a potential treatment against COVID-19.Antiviral Res.178:104791. 10.1016/j.antiviral.2020.10479132275914"/>
 <result pre="A small-molecule oxocarbazate inhibitor of human cathepsin L blocks severe" exact="acute" post="respiratory syndrome and ebola pseudotype virus infection into human"/>
 <result pre="small-molecule oxocarbazate inhibitor of human cathepsin L blocks severe acute" exact="respiratory" post="syndrome and ebola pseudotype virus infection into human embryonic"/>
 <result pre="oxocarbazate inhibitor of human cathepsin L blocks severe acute respiratory" exact="syndrome" post="and ebola pseudotype virus infection into human embryonic kidney"/>
 <result pre="cathepsin L blocks severe acute respiratory syndrome and ebola pseudotype" exact="virus infection" post="into human embryonic kidney 293T cells.Mol. Pharmacol.78319â€&quot;324. 10.1124/mol.110.06426120466822 ShahP."/>
 <result pre="L blocks severe acute respiratory syndrome and ebola pseudotype virus" exact="infection" post="into human embryonic kidney 293T cells.Mol. Pharmacol.78319â€&quot;324. 10.1124/mol.110.06426120466822 ShahP."/>
 <result pre="An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway" exact="epithelial" post="cell cultures and multiple coronaviruses in mice.Sci. Transl. Med.6:eabb5883."/>
 <result pre="RNAs.Cell Res.15193â€&quot;200. 10.1038/sj.cr.729028615780182 ShieJ.-J.FangJ.-M.KuoT.-H.KuoC.-J.LiangP.-H.HuangH.-J.et al. (2005). Inhibition of the severe" exact="acute" post="respiratory syndrome 3CL protease by peptidomimetic Î±,Î²-unsaturated esters.Bioorg. Med."/>
 <result pre="Res.15193â€&quot;200. 10.1038/sj.cr.729028615780182 ShieJ.-J.FangJ.-M.KuoT.-H.KuoC.-J.LiangP.-H.HuangH.-J.et al. (2005). Inhibition of the severe acute" exact="respiratory" post="syndrome 3CL protease by peptidomimetic Î±,Î²-unsaturated esters.Bioorg. Med. Chem.135240â€&quot;5252."/>
 <result pre="10.1038/sj.cr.729028615780182 ShieJ.-J.FangJ.-M.KuoT.-H.KuoC.-J.LiangP.-H.HuangH.-J.et al. (2005). Inhibition of the severe acute respiratory" exact="syndrome" post="3CL protease by peptidomimetic Î±,Î²-unsaturated esters.Bioorg. Med. Chem.135240â€&quot;5252. 10.1016/j.bmc.2005.05.06515994085"/>
 <result pre="10.1016/j.bmc.2005.05.06515994085 ShinJ. S.JungE.KimM.BaricR. S.GoY. Y. (2018). Saracatinib inhibits middle east" exact="respiratory" post="syndrome-coronavirus replication in vitro.Viruses10:283. 10.3390/v1006028329795047 SiuY. L.TeohK. T.LoJ.ChanC. M.KienF.EscriouN.et"/>
 <result pre="The M, E, and N structural proteins of the severe" exact="acute" post="respiratory syndrome coronavirus are required for efficient assembly, trafficking,"/>
 <result pre="M, E, and N structural proteins of the severe acute" exact="respiratory" post="syndrome coronavirus are required for efficient assembly, trafficking, and"/>
 <result pre="E, and N structural proteins of the severe acute respiratory" exact="syndrome" post="coronavirus are required for efficient assembly, trafficking, and release"/>
 <result pre="June 8, 2020) SperberS. J.HaydenF. G. (1989). Comparative susceptibility of" exact="respiratory" post="viruses to recombinant interferons-Î±2b and -Î².J. Interferon Res.9285â€&quot;293. 10.1089/jir.1989.9.2852545792"/>
 <result pre="10.1089/jir.1989.9.2852545792 StocksP. A.RaynesK. J.BrayP. G.ParkB. K.Oâ€™NeillP. M.WardS. A. (2002). Novel" exact="short" post="chain chloroquine analogues retain activity against chloroquine resistant K1"/>
 <result pre="the receptor-binding domain of SARS corona virus spike protein blocks" exact="viral" post="entry into host cells via the human receptor ACE2.Antiviral"/>
 <result pre="Structure and Receptor Binding Comparison and Potential Implications on Neutralizing" exact="Antibody" post="and Vaccine Development.bioRxiv [Preprint]10.1101/2020.02.16.951723 TaiW.HeL.ZhangX.PuJ.VoroninD.JiangS.et al. (2020). Characterization of"/>
 <result pre="novel coronavirus: implication for development of RBD protein as a" exact="viral" post="attachment inhibitor and vaccine.Cell. Mol. Immunol.17613â€&quot;620. 10.1038/s41423-020-0400-432203189 TakanoT.KatohY.DokiT.HohdatsuT. (2013)."/>
 <result pre="Mol. Immunol.17613â€&quot;620. 10.1038/s41423-020-0400-432203189 TakanoT.KatohY.DokiT.HohdatsuT. (2013). Effect of chloroquine on feline" exact="infectious" post="peritonitis virus infection in vitro and in vivo.Antiviral Res.99100â€&quot;107."/>
 <result pre="Immunol.17613â€&quot;620. 10.1038/s41423-020-0400-432203189 TakanoT.KatohY.DokiT.HohdatsuT. (2013). Effect of chloroquine on feline infectious" exact="peritonitis" post="virus infection in vitro and in vivo.Antiviral Res.99100â€&quot;107. 10.1016/j.antiviral.2013.04.01623648708"/>
 <result pre="10.1038/s41423-020-0400-432203189 TakanoT.KatohY.DokiT.HohdatsuT. (2013). Effect of chloroquine on feline infectious peritonitis" exact="virus infection" post="in vitro and in vivo.Antiviral Res.99100â€&quot;107. 10.1016/j.antiviral.2013.04.01623648708 TakashitaE. (2020)."/>
 <result pre="TakanoT.KatohY.DokiT.HohdatsuT. (2013). Effect of chloroquine on feline infectious peritonitis virus" exact="infection" post="in vitro and in vivo.Antiviral Res.99100â€&quot;107. 10.1016/j.antiviral.2013.04.01623648708 TakashitaE. (2020)."/>
 <result pre="C.OoiE. E.LinC.-Y.TanH. C.LingA. E.LimB.et al. (2004). Inhibition of SARS Coronavirus" exact="infection" post="in vitro with clinically approved antiviral drugs.Emerg. Infect. Dis.10581â€&quot;586."/>
 <result pre="ToniatiP.PivaS.CattaliniM.GarrafaE.RegolaF.CastelliF.et al. (2020). Tocilizumab for the treatment of severe COVID-19" exact="pneumonia" post="with hyperinflammatory syndrome and acute respiratory failure: a single"/>
 <result pre="Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory" exact="syndrome" post="and acute respiratory failure: a single center study of"/>
 <result pre="the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and" exact="acute" post="respiratory failure: a single center study of 100 patients"/>
 <result pre="treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute" exact="respiratory" post="failure: a single center study of 100 patients in"/>
 <result pre="antiviral (HTA): functional inhibitor compounds of scaffold protein RACK1 inhibit" exact="herpes" post="simplex virus proliferation.Oncotarget103209â€&quot;3226. 10.18632/oncotarget.2690731143369 UnÃ¼bolM.AyhanM.GuneyE. (2011). Hypoglycemia induced by"/>
 <result pre="10.1097/RHU.0b013e3182098e1f21169846 UrsingJ.RomboL.EksborgS.LarsonL.BruvollA.TarningJ.et al. (2020). High-dose chloroquine for uncomplicated plasmodium falciparum" exact="malaria" post="is well tolerated and causes similar QT interval prolongation"/>
 <result pre="(2016). Discovery of berberine, abamectin and ivermectin as antivirals against" exact="chikungunya" post="and other alphaviruses.Antiviral Res.126117â€&quot;124. 10.1016/j.antiviral.2015.12.01226752081 VassÃ£oR. C.de FrancoM. T.HartzD.ModolellM.SippelA."/>
 <result pre="VassÃ£oR. C.de FrancoM. T.HartzD.ModolellM.SippelA. E.PereiraC. A. (2000). Down-regulation of bgp1a" exact="viral" post="receptor by interferon-Î³ Is related to the antiviral state"/>
 <result pre="Is related to the antiviral state and resistance to mouse" exact="hepatitis" post="virus 3 infection.Virology274278â€&quot;283. 10.1006/viro.2000.046310964771 Villegas-RosalesP. M.MÃ©ndez-TenorioA.Ortega-SotoE.BarrÃ³nB. L. (2012). Bioinformatics"/>
 <result pre="al. (2005). Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spread.Virol. J.2:69. 10.1186/1743-422X-2-6916115318 VuongW.KhanM. B.FischerC.ArutyunovaE.LamerT.ShieldsJ.et al. (2020). Feline"/>
 <result pre="WeissS. R.Navas-MartinS. (2005). Coronavirus pathogenesis and the emerging pathogen severe" exact="acute" post="respiratory syndrome Coronavirus.Microbiol. Mol. Biol. Rev.69635â€&quot;664. 10.1128/MMBR.69.4.635-664.200516339739 WenC. C.KuoY."/>
 <result pre="R.Navas-MartinS. (2005). Coronavirus pathogenesis and the emerging pathogen severe acute" exact="respiratory" post="syndrome Coronavirus.Microbiol. Mol. Biol. Rev.69635â€&quot;664. 10.1128/MMBR.69.4.635-664.200516339739 WenC. C.KuoY. H.JanJ."/>
 <result pre="(2005). Coronavirus pathogenesis and the emerging pathogen severe acute respiratory" exact="syndrome" post="Coronavirus.Microbiol. Mol. Biol. Rev.69635â€&quot;664. 10.1128/MMBR.69.4.635-664.200516339739 WenC. C.KuoY. H.JanJ. T.LiangP."/>
 <result pre="plant terpenoids and lignoids possess potent antiviral activities against severe" exact="acute" post="respiratory syndrome coronavirus.J. Med. Chem.504087â€&quot;4095. 10.1021/jm070295s17663539 collab: WHO (2020a)."/>
 <result pre="terpenoids and lignoids possess potent antiviral activities against severe acute" exact="respiratory" post="syndrome coronavirus.J. Med. Chem.504087â€&quot;4095. 10.1021/jm070295s17663539 collab: WHO (2020a). Clinical"/>
 <result pre="and lignoids possess potent antiviral activities against severe acute respiratory" exact="syndrome" post="coronavirus.J. Med. Chem.504087â€&quot;4095. 10.1021/jm070295s17663539 collab: WHO (2020a). Clinical management"/>
 <result pre="the prefusion conformation.Science367:1260. 10.1126/science.abb250732075877 WuC.-J.JanJ.-T.ChenC.-M.HsiehH.-P.HwangD.-R.LiuH.-W.et al. (2004). Inhibition of severe" exact="acute" post="respiratory syndrome coronavirus replication by niclosamide.Antimicrob. Agents Chemother.482693â€&quot;2696. 10.1128/AAC.48.7.2693-2696.200415215127"/>
 <result pre="prefusion conformation.Science367:1260. 10.1126/science.abb250732075877 WuC.-J.JanJ.-T.ChenC.-M.HsiehH.-P.HwangD.-R.LiuH.-W.et al. (2004). Inhibition of severe acute" exact="respiratory" post="syndrome coronavirus replication by niclosamide.Antimicrob. Agents Chemother.482693â€&quot;2696. 10.1128/AAC.48.7.2693-2696.200415215127 WuD.WuT.LiuQ.YangZ."/>
 <result pre="conformation.Science367:1260. 10.1126/science.abb250732075877 WuC.-J.JanJ.-T.ChenC.-M.HsiehH.-P.HwangD.-R.LiuH.-W.et al. (2004). Inhibition of severe acute respiratory" exact="syndrome" post="coronavirus replication by niclosamide.Antimicrob. Agents Chemother.482693â€&quot;2696. 10.1128/AAC.48.7.2693-2696.200415215127 WuD.WuT.LiuQ.YangZ. (2020)."/>
 <result pre="patients with tocilizumab.Proc. Natl. Acad. Sci. U.S.A.117:202005615. 10.1073/pnas.200561511732350134 YanR.ZhangY.LiY.XiaL.GuoY.ZhouQ. (2020)." exact="Structural" post="basis for the recognition of the SARS-CoV-2 by full-length"/>
 <result pre="optimized dosing design of hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2).Clin. Infect. Dis.9:ciaa237. 10.1093/cid/ciaa23732150618 YogoY.HiranoN.HinoS.ShibutaH.MatumotoM."/>
 <result pre="dosing design of hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2).Clin. Infect. Dis.9:ciaa237. 10.1093/cid/ciaa23732150618 YogoY.HiranoN.HinoS.ShibutaH.MatumotoM. (1977)."/>
 <result pre="design of hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2).Clin. Infect. Dis.9:ciaa237. 10.1093/cid/ciaa23732150618 YogoY.HiranoN.HinoS.ShibutaH.MatumotoM. (1977). Polyadenylate"/>
 <result pre="Dis.9:ciaa237. 10.1093/cid/ciaa23732150618 YogoY.HiranoN.HinoS.ShibutaH.MatumotoM. (1977). Polyadenylate in the Virion RNA of" exact="Mouse" post="Hepatitis Virus.J. Biochem.821103â€&quot;1108. 10.1093/oxfordjournals.jbchem.a131782200604 ZhaL.LiS.PanL.TefsenB.LiY.FrenchN.et al. (2020). Corticosteroid treatment"/>
 <result pre="10.1093/cid/ciaa23732150618 YogoY.HiranoN.HinoS.ShibutaH.MatumotoM. (1977). Polyadenylate in the Virion RNA of Mouse" exact="Hepatitis" post="Virus.J. Biochem.821103â€&quot;1108. 10.1093/oxfordjournals.jbchem.a131782200604 ZhaL.LiS.PanL.TefsenB.LiY.FrenchN.et al. (2020). Corticosteroid treatment of"/>
 <result pre="10.1093/oxfordjournals.jbchem.a131782200604 ZhaL.LiS.PanL.TefsenB.LiY.FrenchN.et al. (2020). Corticosteroid treatment of patients with coronavirus" exact="disease" post="2019 (COVID-19).Med. J. Aust.212416â€&quot;420. 10.5694/mja2.5057732266987 ZhangC.WuZ.LiJ.ZhaoH.WangG. (2020a). Cytokine release"/>
 <result pre="disease 2019 (COVID-19).Med. J. Aust.212416â€&quot;420. 10.5694/mja2.5057732266987 ZhangC.WuZ.LiJ.ZhaoH.WangG. (2020a). Cytokine release" exact="syndrome" post="in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be"/>
 <result pre="and synthesis of dipeptidyl glutaminyl fluoromethyl ketones as potent severe" exact="acute" post="respiratory syndrome coronovirus (SARS-CoV) inhibitors.J. Med. Chem.491198â€&quot;1201. 10.1021/jm050767816451084 ZhuZ.ChakrabortiS.HeY.RobertsA.SheahanT.XiaoX.et"/>
 <result pre="synthesis of dipeptidyl glutaminyl fluoromethyl ketones as potent severe acute" exact="respiratory" post="syndrome coronovirus (SARS-CoV) inhibitors.J. Med. Chem.491198â€&quot;1201. 10.1021/jm050767816451084 ZhuZ.ChakrabortiS.HeY.RobertsA.SheahanT.XiaoX.et al."/>
 <result pre="of dipeptidyl glutaminyl fluoromethyl ketones as potent severe acute respiratory" exact="syndrome" post="coronovirus (SARS-CoV) inhibitors.J. Med. Chem.491198â€&quot;1201. 10.1021/jm050767816451084 ZhuZ.ChakrabortiS.HeY.RobertsA.SheahanT.XiaoX.et al. (2007)."/>
</results>
